Skip to main content

Table 2 Unadjusted measures of abandonment, adherence and persistence according to pharmacy channel

From: Impact of pharmacy channel on adherence to oral oncolytics

Characteristica Specialty Traditional Retail P-value
Number of Patients 11,972 30,394  
Abandonment of Index Prescription <0.001
 Approved Without Challenges, N (%) 11,731 98.0% 28,788 94.7%  
 Initial Challenge but Overcome, N (%) 118 1.0% 875 2.9%  
 Initial Challenge Unknown if Overcome, N (%)b 3 0.0% 43 0.1%  
 Abandoned, N (%)c 97 0.8% 604 2.0%  
 Unknown, N (%)d 23 0.2% 84 0.3%  
Adherence - Proportion of Days Covered between the First and Last Fille  
 Mean (SD) 0.86 (0.2) 0.79 (0.2) <0.001
 Number with >1 fill 9194 22,219  
 Adherent, N (%) 6586 71.6% 12,542 56.4% <0.001
Adherence - Proportion Days Covered between First and Last Fill, N (%) <0.001
 0–0.20 12 0.1% 246 1.1%  
 0.21–0.40 241 2.6% 1273 5.7%  
 0.41–0.60 984 10.7% 3815 17.2%  
 0.61–0.70 733 8.0% 2571 11.6%  
 0.70–0.79 638 6.9% 1772 8.0%  
 0.80–0.90 965 10.5% 2182 9.8%  
 0.90–1.00 5621 61.1% 10,360 46.6%  
Persistencef,g - Time until Discontinuation of Index Oncolytic (days)  
 Number Filling Prescription for Index Oncolytic 11,849 29,663  
 Mean (SD) 186.2 (235.2) 161.8 (218.5) <0.001
 Median 94 83  
 Minimum–Maximum 0–1622 0–1613  
  1. Abbreviations: SD standard deviation, N number of patients
  2. aGroup comparisons were made using 2-sided Pearson chi-square for categorical measures and t-test statistics for continuous measures, P-values are presented for comparisons using traditional retail as reference group
  3. bUnable to determine if hurdle was overcome because follow-up time was censored
  4. cAbandonment measure refers to whether the patient was able to successfully fill prescription within 90 days following an initial challenge (if no, prescription was considered abandoned)
  5. dNo information provided regarding the patient’s first fill status, could not determine if prescription was filled
  6. eAdherence definition excluded patients who only had one prescription fill or abandoned their index prescription (calculation included n = 9194 and n = 22,219 specialty and traditional retail patients, respectively)
  7. fTime until discontinuation (in days) of index oral oncolytic, allowing for a 60-day gap in therapy between the run-out date of the medication and the subsequent fill
  8. gThe definition of persistence excluded patients who abandoned their index oncolytic (calculation included n = 11,849 and n = 29,663 specialty and traditional retail patients, respectively)